Moderna (MRNA) Stock Sinks As Market Gains: Here's Why

Shares of the biotechnology company have appreciated by 28.73% over the course of the past month, outperforming the Medical sector's gain of 3.06% and the S&P 500's gain of 3.25%. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$7.46 per share and revenue of $4.05 billion. These totals would mark changes of +39.5% and -40.83%, respectively, from last year. Our research reveals that these estimate alterations are directly linked with the stock price perform ...